OXB has acquired an FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, from a subsidiary of National Resilience for $4.5 million, adding US GMP drug substance and dedicated fill-finish capacity to its network. The Research Triangle Park site includes two operational GMP suites, a third expansion-ready suite, on-site QC labs, and warehousing, and will serve as OXB’s US hub for clinical and commercial activities, particularly in adeno-associated virus programs. Bedford, Massachusetts, will remain OXB’s AAV center of excellence for process and analytical development. The deal follows OXB’s August 2025 equity raise of roughly £60 million and was funded from existing cash, with key functions targeted to be operational by the first quarter of 2026 and no change to near- or mid-term financial guidance.
The price tag is the tell. For a commercial-ready, FDA-approved site, $4.5 million underscores a buyer’s market in cell and gene therapy manufacturing assets. OXB is effectively pulling forward US commercial capability at a fraction of greenfield cost and time, de-risking capacity expansion while competitors either retrench or digest larger, more complex portfolios. The strategic question is whether this is the moment to lock in scalable US capacity ahead of a new wave of gene therapy launches, or whether it risks adding fixed cost into an uneven demand environment still working through past overbuild.
This matters now because the balance of power in CGT is shifting from discovery to disciplined CMC execution. Sponsors with late-stage AAV assets face a narrow path: higher regulatory scrutiny on potency, empty/full capsid ratios, and comparability, combined with payer expectations for reliable supply and reproducible outcomes. An FDA-approved facility with integrated fill-finish in the US reduces tech transfer friction, shortens time to lot release, and strengthens launch readiness for programs targeting US patients. For Medical Affairs and Market Access teams, dependable manufacturing underpins evidence generation, long-term safety commitments, and payer confidence in therapy availability, which is increasingly tied to outcomes-based contracts and center-of-excellence care models.
For competitors, the move raises the bar on multi-vector, multi-site coverage. OXB’s network across the UK, France, and the US positions it to bid for end-to-end mandates from early development through commercial supply, which is where sponsors prefer a single accountable partner to avoid comparability resets. The addition of North Carolina talent and supply-chain depth adds resilience in a state that has become a manufacturing stronghold for advanced therapies. At the same time, utilization will be the critical metric. After several years of capacity whiplash across biologics and CGT, CDMOs that win anchor programs and move clients through PPQ to commercial lots fastest will set pricing power; those that lag will face rate pressure and idle suites.
The broader industry trend is clear: consolidation and opportunistic asset redeployment in CGT manufacturing, with capital flowing to quality, regulatory maturity, and integrated fill-finish. Sponsors that previously tried to internalize AAV manufacturing are revisiting hybrid models to conserve cash and accelerate filings. If OXB can convert this asset into near-term commercial wins and demonstrate superior tech transfer velocity, it could become a preferred US launch platform for AAV. The next proof points will be disclosed backlog, PPQ starts, and the speed at which the Durham site reaches full commercial readiness. Will 2026 be the year CGT capacity returns to scarcity for high-quality, FDA-proven lines, or does the buyer’s market persist and reset CDMO economics for another cycle?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
